Thyrocare Technologies delivered robust financial performance in the June 2026 quarter, with consolidated net profit surging 34.06% to ₹52.19 crore compared to ₹38.93 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter. The Board of Directors approved these unaudited standalone and consolidated financial results at their meeting held on July 23, 2026, with statutory auditors Price Waterhouse Chartered Accountants LLP issuing an unmodified conclusion. ICICI Securities has upgraded Thyrocare to a 'BUY' rating with a target price of ₹650, raising it from the earlier target of ₹550, citing the company's strong Q1FY27 performance that exceeded expectations. Sequentially, profit also showed positive momentum, rising 5.3% from ₹48.7 crore in the previous quarter. Shares of Thyrocare jumped 5.36% to ₹574.05 following the results announcement, reflecting strong market confidence in the company's performance.
The company's sales revenue increased 24.34% to ₹240.02 crore in Q1 FY2026, up from ₹193.03 crore in the same period last year. As reported by Business Standard, this revenue growth reflects the company's expanding market presence and successful business strategy implementation during the quarter. ICICI Securities highlights that the outperformance was led by strong traction in both pathology segments, with franchises growing at ~27% YoY and partnerships at ~26%. The diagnostic testing services segment remained the largest revenue contributor, generating ₹225.6 crore in segment revenue for the quarter, while the imaging services segment reported revenue of ₹13.48 crore. Diagnostic testing services contributed over 94% of total revenue, with the remainder coming from imaging services and other businesses. Profit before tax (PBT) increased 35.28% YoY to ₹68.29 crore in the quarter ended June 30, 2026.
EBITDA grew 34% YoY to ₹77.27 crore, demonstrating sustained operational momentum despite higher cost pressures. According to the latest financial data, EBITDA margin improved to 32.2% in Q1 FY27 from 29.9% in Q1 FY26, reflecting improved operating efficiency and better cost management. Total expenses increased 19.8% to ₹176.6 crore from ₹147.5 crore a year ago, with cost of materials consumed rising 11.7% YoY to ₹61.9 crore, employee benefit expenses increasing 20% to ₹39.6 crore, and other expenses climbing 30.8% to ₹61 crore. The company processed 55.2 million tests during the quarter, representing a 28% increase year-on-year, while serving 54 lakh patients and conducting 5.52 crore tests, marking 17% and 28% YoY growth respectively. Revenue per test stood at ₹39.8, down 2% from a year earlier, while revenue per patient increased 7% YoY to ₹404. ICICI Securities notes that Thyrocare has forayed into high-value specialty testing with a comprehensive portfolio of 20 specialized tests, including allergy and genomics, and these could account for 15-20% of the company's revenue over the next 3-4 years.
Thyrocare expanded its operational footprint significantly during the quarter, launching new laboratory facilities in Prayagraj, Kurnool and Muzaffarpur to improve testing capacity and turnaround times. As reported by Business Standard, the company also expanded its specialty diagnostics portfolio by introducing new technologies, including gut microbiome testing and whole exome sequencing. The Pathology segment demonstrated strong growth with 26% expansion, while franchise revenue increased 27% to ₹142.8 crore and partnership revenue rose 26% compared with the year-ago period. The diagnostic testing services segment results before tax and exceptional items stood at ₹61.90 crore for the quarter. Rahul Guha, MD & CEO, Thyrocare Technologies stated, "Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway."
Separately, Thyrocare's board approved evaluating a proposed demerger of the radiology business housed under its wholly owned subsidiary, Nueclear Healthcare Ltd (NHL), through a slump sale or business transfer outside the group, subject to regulatory approvals. For FY26, NHL's standalone revenue declined 6% YoY to ₹44.6 crore, while its net profit improved to ₹6.16 crore from a near breakeven level in FY25. Employee costs increased due to annual salary increments as well as expansion of the laboratory network and specialty diagnostics business. At its 26th AGM on June 30, 2026, shareholders approved a final dividend of ₹7.00 per share and amended the Memorandum of Association to expand the diagnostic facility business objects. ICICI Securities reports that the board has given its nod to evaluate the demerger of its imaging arm, Nueclear Healthcare Ltd; the process is likely to be completed in six months. Management has maintained guidance of 15–20% revenue growth in FY27. The company operates as an advanced fully automated laboratory chain with a quarterly active franchise count of approximately 11,700 and processed 55.2 million diagnostic and screening investigations in Q1FY27.
